FDA Approves Treosulfan with Fludarabine As a Preparative Regimen for alloHSCT in Adult and Paediatric Patients with AML or MDS By Ogkologos - March 13, 2025 793 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MC-FludT.14/L Trial II Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR New on NCI’s Websites for November 2024 November 1, 2024 Prevalence of ALK Alterations in Non-Small Cell Lung Cancer Determined March 24, 2021 FDA Approves a Fixed-Dose Combination of Nivolumab and Relatlimab for Unresectable... April 12, 2022 Happy New Year From Our Team January 4, 2021 Load more HOT NEWS Sacituzumab Govitecan Approved for Metastatic Triple-Negative Breast Cancer FDA Approval of KRAS Inhibitor Sotorasib for Lung Cancer Hailed as... Bus Driver Finds Out Teen With Cancer Can’t Afford Prom &... Singer Surprises 6-Year-Old Fan Who Beat Cancer With Trip To Disney
